The Boards of Directors of Aegros Bidco Limited (a newly incorporated company to be indirectly owned by DBAY Affiliates and the ERES IV Fund) and Alliance Pharma plc have announced that they have reached agreement on the terms and conditions of a recommended acquisition by Bidco for the entire issued and to be issued ordinary share capital of Alliance. It is intended that the acquisition will be implemented by way of a Scheme of Arrangement, subject to a Sanction Hearing to be held on 12th May 2025.
The terms of the scheme are as follows: –
For each Alliance Pharma share held    –   64.75p in cash
Subject to the Scheme becoming effective the cash will be credited to client accounts on or around 28th May 2025. We will remove the Alliance Pharma shares once the cash has been credited. If you require any further information, you may contact us either by letter, telephone or email as detailed below quoting ‘Alliance Pharma’ in the subject box.
Corporate Action Administration
Direct Line – 0161-819-4850 | Email: caisa@pilling.co.uk